AOD9604 is a modified version of AOD9604 fragment 176-191, which is itself a smaller, modified piece of human growth hormone (was originally developed as an anti-obesity drug due to its lipolytic (fat burning) properties. . There is also no evidence that the body forms antibodies against AOD9604 as it is similar enough in structure to HGH to avoid stimulating an immune system response
$50 USD
Out of stock
Not for human or veterinary use. Made in USA
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
AOD9604 is a modified version of AOD9604 fragment 176-191, which is itself a smaller, modified piece of human growth hormone (was originally developed as an anti-obesity drug due to its lipolytic (fat burning) properties. . There is also no evidence that the body forms antibodies against AOD9604 as it is similar enough in structure to HGH to avoid stimulating an immune system response
Peptide Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Disulfide Bridge: Cys7–Cys15
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.12 g/mol
PubChem CID: 16131447
CAS Number: 386264-39-7
1. AOD9604 and Obesity
AOD9604 was originally developed as an analogue of HGH with the express purpose of fighting fat. Phase 2b clinical trials were completed in Australia testing the drug in 300 obese individuals. The results of once-daily administration of the peptide for 12 weeks showed that the drug tripled weight loss when compared to placebo and that the rate of weight loss remained steady during the trial period [3][4]. This suggests resistance to the peptide is unlikely and that longer-term treatment could result in even greater weight loss.
Research in genetically obese mice suggests AOD9604 does not work solely by affecting beta-3-adrenergic receptors on white fat. Though initially believed to bind to these receptors and increase metabolism, fat loss still occurred in mice lacking these receptors when given AOD9604 [5]. This suggests at least one other mechanism is involved, potentially including indirect activation of apoptosis in white fat cells.
Body weight change in obese mice over 14-day treatment period with AOD9604 (squares), HGH (triangles), and placebo (circles).
Source: Oxford Academic
2. Joint Pain and Function
Research in rats shows that AOD9604 injections into arthritic joints may work in synergy with existing therapies to reduce pain, improve joint function, and enhance quality of life [6]. Changes seen in both clinical exams and microscopic cartilage structure indicate AOD9604 may treat and even prevent osteoarthritis. While effective on its own, AOD9604 appears to be more beneficial when combined with other therapies. The mechanism behind this synergy remains unclear but could reveal new approaches to improving cartilage regeneration.
3. AOD9604 and Heart Disease
Although reducing fat mass inherently lowers heart disease risk, AOD9604 may offer additional cardiovascular benefits independent of fat loss. It is thought to positively influence metabolism in ways that help reduce heart disease complications, similar to drugs like pioglitazone and acipimox. The alternate fat-loss pathway not dependent on beta-3-adrenergic receptor activation might also be responsible for improving metabolic outcomes [7].
AOD9604 has minimal side effects and shows high oral and subcutaneous bioavailability in mice. Dosages in mice do not scale to humans. AOD9604 from Peptide Sciences is sold for educational and scientific research use only—not for human consumption. Only purchase AOD9604 if you are a licensed researcher.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Heike Stier
Stier Heike studied Biology and holds a Ph.D. in Neurobiology (NMI Reutlingen / University of Hohenheim) and a Master’s in Bioinformatics (University of Applied Sciences – TFH Berlin). She worked as a Post-Doc in several national and international labs in Developmental Neurobiology (NMI Reutlingen, School of Medicine – University of Utah) and in Bioinformatics (Institute of Bioinformatics – Charité, Berlin). Dr. Heike led a pioneering study on the safety and tolerability of the hexadecapeptide AOD9604 in humans.
In 2007, she joined A&R, where she was responsible for the regulatory affairs of herbal medicinal products, with a broad knowledge of adjacent product categories including medical devices and supplements. Dr. Heike Stier currently works in regulatory affairs for herbal medicinal products at analyze & realize GmbH.
Disclaimer:
Dr. Heike Stier is referenced as one of the leading scientists involved in the research and development of AOD9604. She does not endorse, advocate, or promote the purchase, sale, or use of this product for any reason. There is no affiliation, endorsement, or relationship—implied or explicit—between Peptide Sciences and Dr. Heike Stier. The purpose of this citation is solely to acknowledge and credit the scientific contributions of researchers studying this peptide. Dr. Heike is cited in reference [8].
F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. Link
H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7–15, Apr. 2013. Link
“Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. Link
R. Zieba, “Obesity: a review of currently used antiobesity drugs and new compounds in clinical development,” Postepy Hig. Med. Dosw., vol. 61, pp. 612–626, Oct. 2007. Link
M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. Link
D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015. Link
M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S–149S, Jun. 2006. Link
H. Stier, E. Vos, D. Kenley. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” Journal of Endocrinology and Metabolism, North America, vol. 3, Apr. 2013. Link
Disclaimer:
All articles and product information provided on this website are for informational and educational purposes only.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction into humans or animals is strictly forbidden by law.
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
AOD9604 is a modified version of AOD9604 fragment 176-191, which is itself a smaller, modified piece of human growth hormone (was originally developed as an anti-obesity drug due to its lipolytic (fat burning) properties. . There is also no evidence that the body forms antibodies against AOD9604 as it is similar enough in structure to HGH to avoid stimulating an immune system response
Peptide Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Disulfide Bridge: Cys7–Cys15
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.12 g/mol
PubChem CID: 16131447
CAS Number: 386264-39-7
1. AOD9604 and Obesity
AOD9604 was originally developed as an analogue of HGH with the express purpose of fighting fat. Phase 2b clinical trials were completed in Australia testing the drug in 300 obese individuals. The results of once-daily administration of the peptide for 12 weeks showed that the drug tripled weight loss when compared to placebo and that the rate of weight loss remained steady during the trial period [3][4]. This suggests resistance to the peptide is unlikely and that longer-term treatment could result in even greater weight loss.
Research in genetically obese mice suggests AOD9604 does not work solely by affecting beta-3-adrenergic receptors on white fat. Though initially believed to bind to these receptors and increase metabolism, fat loss still occurred in mice lacking these receptors when given AOD9604 [5]. This suggests at least one other mechanism is involved, potentially including indirect activation of apoptosis in white fat cells.
Body weight change in obese mice over 14-day treatment period with AOD9604 (squares), HGH (triangles), and placebo (circles).
Source: Oxford Academic
2. Joint Pain and Function
Research in rats shows that AOD9604 injections into arthritic joints may work in synergy with existing therapies to reduce pain, improve joint function, and enhance quality of life [6]. Changes seen in both clinical exams and microscopic cartilage structure indicate AOD9604 may treat and even prevent osteoarthritis. While effective on its own, AOD9604 appears to be more beneficial when combined with other therapies. The mechanism behind this synergy remains unclear but could reveal new approaches to improving cartilage regeneration.
3. AOD9604 and Heart Disease
Although reducing fat mass inherently lowers heart disease risk, AOD9604 may offer additional cardiovascular benefits independent of fat loss. It is thought to positively influence metabolism in ways that help reduce heart disease complications, similar to drugs like pioglitazone and acipimox. The alternate fat-loss pathway not dependent on beta-3-adrenergic receptor activation might also be responsible for improving metabolic outcomes [7].
AOD9604 has minimal side effects and shows high oral and subcutaneous bioavailability in mice. Dosages in mice do not scale to humans. AOD9604 from Peptide Sciences is sold for educational and scientific research use only—not for human consumption. Only purchase AOD9604 if you are a licensed researcher.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Heike Stier
Stier Heike studied Biology and holds a Ph.D. in Neurobiology (NMI Reutlingen / University of Hohenheim) and a Master’s in Bioinformatics (University of Applied Sciences – TFH Berlin). She worked as a Post-Doc in several national and international labs in Developmental Neurobiology (NMI Reutlingen, School of Medicine – University of Utah) and in Bioinformatics (Institute of Bioinformatics – Charité, Berlin). Dr. Heike led a pioneering study on the safety and tolerability of the hexadecapeptide AOD9604 in humans.
In 2007, she joined A&R, where she was responsible for the regulatory affairs of herbal medicinal products, with a broad knowledge of adjacent product categories including medical devices and supplements. Dr. Heike Stier currently works in regulatory affairs for herbal medicinal products at analyze & realize GmbH.
Disclaimer:
Dr. Heike Stier is referenced as one of the leading scientists involved in the research and development of AOD9604. She does not endorse, advocate, or promote the purchase, sale, or use of this product for any reason. There is no affiliation, endorsement, or relationship—implied or explicit—between Peptide Sciences and Dr. Heike Stier. The purpose of this citation is solely to acknowledge and credit the scientific contributions of researchers studying this peptide. Dr. Heike is cited in reference [8].
F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. Link
H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7–15, Apr. 2013. Link
“Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. Link
R. Zieba, “Obesity: a review of currently used antiobesity drugs and new compounds in clinical development,” Postepy Hig. Med. Dosw., vol. 61, pp. 612–626, Oct. 2007. Link
M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. Link
D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015. Link
M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S–149S, Jun. 2006. Link
H. Stier, E. Vos, D. Kenley. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” Journal of Endocrinology and Metabolism, North America, vol. 3, Apr. 2013. Link
Disclaimer:
All articles and product information provided on this website are for informational and educational purposes only.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction into humans or animals is strictly forbidden by law.
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
From $119 USD - $140 USD
From $47 USD - $55 USD
From $43 USD - $50 USD
From $43 USD - $50 USD
From $43 USD - $50 USD
From $149 USD - $175 USD
Receive all the latest information on events, sales, & offers.
Mon - Fri 9AM - 4PM PST
Mon - Fri (Excluding holidays)
Orders placed and paid after 12PM PST are shipped the following business day
© 2025
Ai-Peptides.com. All Rights Reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Ai-Peptides is a chemical supplier. Ai-Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. AiPeptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
